Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centene Corp (CNC) vs T Rowe Price Group Inc (TROW) Price & Performance

Centene CorpTrade
T Rowe Price Group IncTrade

Price performance (Past 24H)

Key statistics

Centene Corp vs T Rowe Price Group Inc — how do they compare? Centene Corp trades at $66.84 (market cap $33.93B), while T Rowe Price Group Inc trades at $118.61 (market cap $24.87B). The key difference: Centene Corp is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.48% dividend while Centene Corp pays none. Which is the better fit depends on your goals.

CNCTROW
Market Cap
$33.93B$24.87B
Sector
HealthFinancials
52-Week High
$68.72$120.16
52-Week Low
$25.21$86.19
Enterprise Value
$26.56B$21.58B
Dividend Yield
4.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Centene Corp

Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.

Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.

T Rowe Price Group Inc

T. Rowe Price (TROW) trades at $113.65, down 4.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported June 2026 AUM of $1.89 trillion (PRNewsWire, 2026-07-13), showing steady growth. Recent earnings beat expectations in Q1 2026 with EPS of $2.52 versus $2.33 forecast. Valuation ratios remain attractive with a P/E of 12.19 and ROE of 19.31%, supported by strong cash flow trends.

TROW presents a mixed outlook: analyst consensus is cautious with 63% hold ratings and a $109.17 price target below current levels, but fundamentals like rising net cash flow to $909M in 2026 and a 28.28% net margin offer stability. Key risks include equity outflows and market volatility, while the dividend yield near 4.9% (Investors Business Daily, 2026-06-10) provides income appeal. Upside depends on sustained AUM growth and execution against competition.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW